Lilly Invests In MiNA To Fund Protein-Upregulating RNA Programs

  • Eli Lilly And Co LLY is set to invest $15 million in its small activating RNA (saRNA) partner, MiNA Therapeutics. 
  • The investment comes two months after Lilly agreed to pay $25 million upfront to work with MiNA on up to five targets.
  • MiNA will use the money to advance its internal pipeline of saRNA therapeutics, led by a drug designed to cut immunosuppression by raising levels of the C/EBP-⍺ master regulator of myeloid cell differentiation.
  • Price Action: LLY shares are up 0.05% at $234.07 during the market session on the last check Tuesday.

Posted In: BriefsBiotechNewsHealth CareFinancingContractsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.